Valuation: Grace Therapeutics, Inc.

Market Cap 54.71M 38.52M 33.67M 30.95M 28.85M 3.67B 55.54M 372M 144M 1.8B 145M 141M 6.21B P/E 2027 *
-4.56x
P/E 2028 * -4.34x
Enterprise Value 54.71M 38.52M 33.67M 30.95M 28.85M 3.67B 55.54M 372M 144M 1.8B 145M 141M 6.21B EV / Sales 2027 *
-
EV / Sales 2028 * 6.98x
Free-Float
74.27%
Yield 2027 *
-
Yield 2028 * -
1 day+5.80%
1 week-0.42%
Current month+4.41%
1 month-0.84%
3 months-53.80%
6 months-35.25%
Current year-31.50%
1 week 2.08
Extreme 2.0782
2.44
1 month 2.08
Extreme 2.0782
2.48
Current year 1.79
Extreme 1.79
5.18
1 year 1.79
Extreme 1.79
5.18
3 years 1.72
Extreme 1.72
5.18
5 years 1.72
Extreme 1.72
27.74
10 years 1.72
Extreme 1.72
161.11
Manager TitleAgeSince
Chief Executive Officer 54 2023-04-03
Director of Finance/CFO 54 2024-01-04
Chief Tech/Sci/R&D Officer 64 2023-05-07
Director TitleAgeSince
Chairman 57 -
Director/Board Member 54 2023-04-03
Director/Board Member 59 2023-10-09
Date Insider Type Main position Quantity % Market Cap.
01-11Option

Director

10,000 0.0646%
01-11Option

Chairman

10,000 0.0646%
01-11Option

Director

10,000 0.0646%
Change 5-day change 1-year change 3-year change Capi.($)
+5.80%-0.42%-24.28%-24.33% 38.57M
+0.68%+5.92%+77.86%+139.22% 59.1B
+2.32%+5.03%+75.26%+91.40% 55.19B
+3.86%+6.93%-11.32%-9.53% 24.67B
+4.30%+7.95%+14.11%+437.83% 24.19B
+4.74%+13.68%+43.36%-4.67% 19.69B
-0.29%+9.78%+43.90%-28.41% 17.56B
0.00%+20.78%+186.15%+361.42% 16.22B
+3.50%+1.97%+21.02%+191.95% 14.04B
+6.72%+19.38%+37.85% - 14.84B
Average +3.16%+7.71%+46.39%+128.32% 24.55B
Weighted average by Cap. +2.46%+6.47%+58.31%+136.95%

Financials

2027 *2028 *
Net sales - 7.83M 5.52M 4.82M 4.43M 4.13M 525M 7.95M 53.19M 20.68M 258M 20.7M 20.26M 889M
Net income -12.76M -8.98M -7.85M -7.22M -6.73M -855M -12.95M -86.64M -33.68M -420M -33.72M -32.99M -1.45B -20.46M -14.41M -12.6M -11.57M -10.79M -1.37B -20.77M -139M -54.02M -674M -54.08M -52.92M -2.32B
Net Debt - -
Logo Grace Therapeutics, Inc.
Grace Therapeutics, Inc. is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its novel drug delivery technologies have the potential to improve the performance of marketed drugs by achieving faster onset of action, and reduced side effects. Its lead clinical asset, GTx-104, is an intravenous infusion targeting aneurysmal Subarachnoid Hemorrhage (aSAH), a rare and life-threatening medical emergency in which bleeding occurs over the surface of the brain in the subarachnoid space between the brain and skull. The nanoparticle technology of GTx-104 facilitates aqueous formulation of insoluble nimodipine for a standard peripheral IV infusion. Its other pipeline includes GTX-102, which is targeted as the first potential therapy for the treatment of ataxia-telangiectasia (AT) in a pediatric population and GTx-101, which is a topical administration via a bioadhesive, film-forming polymer, for the treatment of pain associated with postherpetic neuralgia.
Employees
5
Date Price Change Volume
26-07-02 US$2.370 +5.80% 268,970
26-07-01 US$2.240 -1.32% 251,044
26-06-30 US$2.270 -1.30% 409,178
26-06-29 US$2.300 -3.36% 994,744
26-06-26 US$2.380 +0.42% 269,628
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
3.362CAD
Average target price
8.447CAD
Spread / Average Target
+151.25%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GRCE Stock